COM:EDGEWISETX
Edgewise Therapeutics
- Stock
Last Close
31.98
22/11 21:00
Market Cap
2.01B
Beta: -
Volume Today
352.86K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 1.12M - | 2.71M 141.34% | 4.97M 83.44% | 5.07M 1.83% | ||
average receivables | ||||||
book value per share | -0.83 - | -0.72 13.39% | 7.31 1,118.81% | 6.47 11.52% | 0.01 99.92% | |
capex per share | -0.01 - | -0.00 50.74% | -0.02 308.34% | -0.10 481.33% | -0.00 99.91% | |
capex to depreciation | -1.46 - | -1.10 25.02% | -2.46 123.81% | -10.31 319.75% | -3.32 67.82% | |
capex to operating cash flow | 0.02 - | 0.01 29.32% | 0.02 43.72% | 0.11 428.52% | 0.06 40.70% | |
capex to revenue | ||||||
cash per share | 1.16 - | 2.77 138.37% | 14.55 424.85% | 12.72 12.55% | 0.00 99.96% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.01 - | 0.02 32.60% | ||||
debt to equity | 0.01 - | 0.02 33.56% | ||||
dividend yield | ||||||
earnings yield | -0.02 - | -0.01 21.48% | -0.07 502.00% | -0.03 56.27% | -0.00 99.55% | |
enterprise value | 586.49M - | 1.29B 120.31% | 292.61M 77.35% | 131.59M 55.03% | 697.06B 529,621.10% | |
enterprise value over ebitda | -59.84 - | -75.97 26.96% | -6.77 91.09% | -5.96 11.98% | -6.10K 102,173.69% | |
ev to operating cash flow | -63.95 - | -88.29 38.07% | -8.73 90.11% | -2.50 71.37% | -7.58K 303,135.20% | |
ev to sales | ||||||
free cash flow per share | -0.46 - | -0.32 30.70% | -0.91 185.83% | -1.09 19.21% | -0.00 99.86% | |
free cash flow yield | -0.02 - | -0.01 30.70% | -0.06 461.18% | -0.12 103.74% | -0.00 99.88% | |
graham net net | -0.87 - | -0.76 12.70% | 14.26 1,972.68% | 12.34 13.45% | 0.00 99.96% | |
graham number | 2.95 - | 2.43 17.54% | 13.59 458.92% | 6.47 52.42% | 0.01 99.79% | |
income quality | 0.94 - | 0.85 9.56% | 0.78 8.43% | 0.78 0.57% | 0.92 17.97% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -5.50 - | |||||
interest debt per share | 0.16 - | 0.00 99.95% | ||||
inventory turnover | ||||||
invested capital | 0.01 - | 0.02 33.56% | ||||
market cap | 610.14M - | 1.40B 128.96% | 573.40M 58.96% | 479.13M 16.44% | 697.14B 145,400.99% | |
net current asset value | -17.35M - | -34.91M 101.20% | 269.94M 873.22% | 331.56M 22.83% | 305.79M 7.77% | |
net debt to ebitda | 2.41 - | 6.17 155.62% | 6.50 5.33% | 15.74 142.26% | 0.71 95.52% | |
net income per share | -0.47 - | -0.37 21.48% | -1.12 206.62% | -0.29 74.42% | -0.00 99.45% | |
operating cash flow per share | -0.45 - | -0.31 30.31% | -0.89 184.13% | -0.98 9.99% | -0.00 99.85% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.39 - | -0.13 66.36% | -0.15 13.60% | -0.04 71.61% | -0.29 602.32% | |
revenue per share | ||||||
roe | 0.56 - | 0.51 9.34% | -0.15 130.10% | -0.04 71.08% | -0.31 607.43% | |
roic | 0.58 - | 0.51 10.98% | -0.16 130.26% | -0.05 68.23% | -0.35 604.37% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | -0.83 - | -0.72 13.39% | 7.31 1,118.81% | 6.47 11.52% | 0.01 99.92% | |
stock based compensation to revenue | ||||||
tangible asset value | -16.85M - | -33.42M 98.30% | 274.38M 921.01% | 346.72M 26.36% | 318.83M 8.04% | |
tangible book value per share | -0.83 - | -0.72 13.39% | 7.31 1,118.81% | 6.47 11.52% | 0.01 99.92% | |
working capital | 22.91M - | 125.30M 446.91% | 270.27M 115.69% | 335.36M 24.08% | 310.23M 7.50% |
All numbers in (except ratios and percentages)